Ceftazidime/avibactam: a novel cephalosporin/nonbeta-lactam beta-lactamase inhibitor for the treatment of complicated urinary tract infections and complicated intra-abdominal infections.

August 27, 2016 at 12:27 pm

Drug Des Devel Ther. 2016 Jul 26;10:2379-86.

Hidalgo JA1, Vinluan CM2, Antony N3.

Author information

1UTEP/UT Austin Cooperative Pharmacy Program, College of Health Sciences, University of Texas at El Paso, El Paso; Department of Pharmacy, College of Pharmacy, The University of Texas at Austin, Austin.

2UTEP/UT Austin Cooperative Pharmacy Program, College of Health Sciences, University of Texas at El Paso, El Paso; Department of Pharmacy, College of Pharmacy, The University of Texas at Austin, Austin; Department of Internal Medicine, Texas Tech University Health Sciences Center, El Paso, TX, USA.

3Department of Internal Medicine, Texas Tech University Health Sciences Center, El Paso, TX, USA.

Abstract

There has been greater interest in developing additional antimicrobial agents due to the increasing health care costs and resistance resulting from bacterial pathogens to currently available treatment options. Gram-negative organisms including Enterobacteriaceae and Pseudomonas aeruginosa are some of the most concerning threats due to their resistance mechanisms: extended-spectrum beta-lactamase production and Klebsiella pneumoniae carbapenemase enzymes. Ceftazidime is a third-generation broad-spectrum cephalosporin with activity against P. aeruginosa and avibactam is a novel nonbeta-lactam beta-lactamase inhibitor. Avycaz(®), the trade name for this new combination antibiotic, restores the activity of ceftazidime against some of the previously resistant pathogens. Avycaz was approved in 2015 for the treatment of complicated urinary tract infections, including pyelonephritis, and complicated intra-abdominal infections with the addition of metronidazole in patients with little to no other treatment options. This review article assesses the clinical trials and data that led to the approval of this antibiotic, in addition to its spectrum of activity and limitations.

PDF

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4970634/pdf/dddt-10-2379.pdf

Entry filed under: Antimicrobianos, Bacterias, Bacteriemias, Epidemiología, Infecciones intraabdominales, Infecciones urinarias, Metodos diagnosticos, Resistencia bacteriana, Sepsis, Update. Tags: .

The Alpha-defensin Test for Periprosthetic Joint Infections Is Not Affected by Prior Antibiotic Administration. Body mass and weight thresholds for increased prosthetic joint infection rates after primary total joint arthroplasty.


Calendar

August 2016
M T W T F S S
« Jul   Sep »
1234567
891011121314
15161718192021
22232425262728
293031  

Most Recent Posts


%d bloggers like this: